litlas
ログインアカウント作成

Michael Millward

1993–2025 年に発表

115
論文数
18,397
被引用数
63
h 指数
109
i10 指数

被引用数

Michael Millward の年別被引用数1994 年: 被引用 2 件1995 年: 被引用 2 件1996 年: 被引用 2 件1997 年: 被引用 3 件1998 年: 被引用 6 件1999 年: 被引用 9 件2000 年: 被引用 10 件2001 年: 被引用 14 件2002 年: 被引用 16 件2003 年: 被引用 10 件2004 年: 被引用 14 件2005 年: 被引用 30 件2006 年: 被引用 32 件2007 年: 被引用 39 件2008 年: 被引用 50 件2009 年: 被引用 62 件2010 年: 被引用 68 件2011 年: 被引用 62 件2012 年: 被引用 83 件2013 年: 被引用 210 件2014 年: 被引用 226 件2015 年: 被引用 296 件2016 年: 被引用 250 件2017 年: 被引用 299 件2018 年: 被引用 250 件2019 年: 被引用 688 件2020 年: 被引用 751 件2021 年: 被引用 730 件2022 年: 被引用 649 件2023 年: 被引用 491 件2024 年: 被引用 784 件2025 年: 被引用 306 件2026 年: 被引用 11 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,143 件、この内訳の 24.4%中国: 引用元論文 857 件、この内訳の 9.8%イタリア: 引用元論文 585 件、この内訳の 6.7%オーストラリア: 引用元論文 555 件、この内訳の 6.3%ドイツ: 引用元論文 498 件、この内訳の 5.7%イギリス: 引用元論文 480 件、この内訳の 5.5%フランス: 引用元論文 407 件、この内訳の 4.7%オランダ: 引用元論文 328 件、この内訳の 3.7%スペイン: 引用元論文 290 件、この内訳の 3.3%カナダ: 引用元論文 248 件、この内訳の 2.8%スイス: 引用元論文 244 件、この内訳の 2.8%日本: 引用元論文 203 件、この内訳の 2.3%
0%24.4%その他 22%

機関

分野

  • Medicine52.1%
  • Biochemistry, Genetics and Molecular Biology38.1%
  • Immunology and Microbiology5.4%
  • Computer Science0.7%
  • Engineering0.7%
  • Materials Science0.6%
  • その他2.4%

トピック

  • Melanoma and MAPK Pathways9.8%
  • Cancer Immunotherapy and Biomarkers7.6%
  • Cutaneous Melanoma Detection and Management4.9%
  • Immunotherapy and Immune Responses4%
  • Lung Cancer Treatments and Mutations4%
  • CAR-T cell therapy research3.7%
  • その他66%

共著者

全論文

検索で開く
  1. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    著者: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymyr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, Michelle Casey, Danièle Ouellet, Anne‐Marie Martin, Ngocdiep T. Le, Kiran Patel, Keith T. Flaherty - New England Journal of Medicine 2014 被引用: 1,871

  2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    著者: Axel Hauschild, Jean‐Jacques Grob, Lev Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U. Blank, Wilson H. Miller, Eckhart Kaempgen, Salvador Martín‐Algarra, Bogusława Karaszewska, Cornelia Mauch, Vanna Chiarion‐Sileni, Anne-Marie Martin, S. Swann, Patricia Haney, Beloo Mirakhur, Mary Guckert, Vicki Goodman, Paul B. Chapman - The Lancet 2012 被引用: 2,960

  3. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

    著者: Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Michele Maio, Mark R. Middleton, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael Millward, Nikhil I. Khushalani, Paola Queirolo, Maurice Lobo, Veerle de Pril, John T. Loffredo, James Larkin, Jeffrey S. Weber - The Lancet Oncology 2020 被引用: 525

  4. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    著者: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, S. Swann, Jeffrey J. Legos, Fan Jin, Bijoyesh Mookerjee, Keith T. Flaherty - The Lancet 2015 被引用: 1,386

  5. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

    著者: James Larkin, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey S. Weber - Clinical Cancer Research 2023 被引用: 180

  6. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

    著者: Mengzhao Wang, James Chih-Hsin Yang, Paul L. Mitchell, Jian Fang, D. Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Viola W. Zhu, Michael Millward, Yun Fan, Wen-Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Lyudmila Bazhenova, Chee Khoon Lee, Bo Gao, Yan Xu, Wei-Hsun Hsu, Li Zheng, Pasi A. Jänne - Cancer Discovery 2022 被引用: 119

  7. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

    著者: Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna C. Pavlick, Steven O’Day, Samuel C. Blackman, C. Martin Curtis, Peter F. Lebowitz, Bo Ma, Danièle Ouellet, Richard Kefford - The Lancet 2012 被引用: 933

  8. Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations

    著者: Timothy A. Yap, David J. Kwiatkowski, Jayesh Desai, Ibiayi Dagogo‐Jack, Michael Millward, Hedy L. Kindler, Anthony W. Tolcher, Sophia Frentzas, Archie Thurston, Len Post, F Andrew Dorr - Cancer Research 2023 被引用: 64

  9. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment

    著者: Rachael M. Zemek, Emma de Jong, Wee Loong Chin, Iona S. Schuster, Vanessa S. Fear, Thomas Casey, Cath Forbes, Sarah Dart, Connull Leslie, Ayham Zaitouny, Michael Small, Louis Boon, Alistair R. R. Forrest, Daithi O. Muiri, Mariapia A. Degli‐Esposti, Michael Millward, Anna K. Nowak, Timo Lassmann, Anthony Bosco, Richard Lake, W. Joost Lesterhuis - Science Translational Medicine 2019 被引用: 216

  10. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

    著者: Jayesh Desai, Hui Gan, Catherine Barrow, Michael B. Jameson, Victoria Atkinson, Andrew Haydon, Michael Millward, Stephen Begbie, Michael P. Brown, Ben Markman, W. K. Patterson, Andrew Hill, Lisa G. Horvath, Adnan Nagrial, Gary Richardson, Christopher Jackson, Michael Friedländer, Phillip Parente, Ben Tran, Lai Wang, Yunxin Chen, Zhiyu Tang, Wendy Huang, John Wu, Dewan Zeng, Lusong Luo, Benjamin Solomon - Journal of Clinical Oncology 2020 被引用: 109

  11. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity

    著者: W. Joost Lesterhuis, Anthony Bosco, Michael Millward, Michael Small, Anna K. Nowak, Richard Lake - Nature Reviews Drug Discovery 2017 被引用: 258

  12. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

    著者: C. Owen, Alexander N. Shoushtari, D Chauhan, David Palmieri, Belinda Lee, Maartje W. Rohaan, Joanna Mangana, Victoria Atkinson, Farzana Y. Zaman, Arissa Young, Christoph Höeller, Peter Hersey, R. Dummer, Muhammad A. Khattak, Michael Millward, Sapna P. Patel, Andrew Haydon, Douglas B. Johnson, Serigne Lo, Christian U. Blank, Shahneen Sandhu, Matteo S. Carlino, James Larkin, Alexander M. Menzies, Georgina V. Long - Annals of Oncology 2020 被引用: 110

  13. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

    著者: Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Michael Millward, Wei Zhang, Ling Gao, Amanda K. Sykes, Melinda D. Willard, Danni Yu, Andrew E. Schade, KrisAnne Crowe, Daniel L. Flynn, Michael D. Kaufman, James R. Henry, Sheng-Bin Peng, Karim A. Benhadji, Ilaria Conti, Michael S. Gordon, Ramón V. Tiu, David S. Hong - Molecular Cancer Therapeutics 2019 被引用: 87

  14. A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors

    著者: Sophia Frentzas, Hui Gan, Rasha Cosman, Jermaine Coward, Ben Tran, Michael Millward, Yiting Zhou, Wenjing Wang, Dennis Xia, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Jayesh Desai - Cell Reports Medicine 2023 被引用: 39

  15. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors

    著者: Jenny Lee, Alexander M. Menzies, Matteo S. Carlino, Ashleigh C. McEvoy, Shahneen Sandhu, Alison M. Weppler, Russell J. Diefenbach, Sarah‐Jane Dawson, Richard Kefford, Michael Millward, Zeyad Al‐Ogaili, Thien Tra, Elin S. Gray, Stephen Q. Wong, Richard A. Scolyer, Georgina V. Long, Helen Rizos - Clinical Cancer Research 2020 被引用: 82

  16. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

    著者: Jean‐Charles Soria, Hui Gan, Sarah P. Blagden, Ruth Plummer, H.T. Arkenau, Marie Ranson, T.R. Jeffry Evans, Gérard Zalcman, Rastislav Bahleda, Antoine Hollebecque, Charlotte Lemech, Emma Dean, Jennifer Brown, D. Gibson, Vijay Peddareddigari, Sonya R Murray, Noelia Nebot, Jolly Mazumdar, Leslie Swartz, K R Auger, Ronald A. Fleming, R. Singh, Michael Millward - Annals of Oncology 2016 被引用: 145

  17. Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice

    著者: Rachael M. Zemek, Wee Loong Chin, Vanessa S. Fear, Ben Wylie, Thomas Casey, Cath Forbes, Caitlin M. Tilsed, Louis Boon, Belinda B. Guo, Anthony Bosco, Alistair R. R. Forrest, Michael Millward, Anna K. Nowak, Richard Lake, Timo Lassmann, W. Joost Lesterhuis - Nature Communications 2022 被引用: 47

  18. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

    著者: Elin S. Gray, Helen Rizos, Anna Reid, Suzanah C. Boyd, Michelle R. Pereira, Johnny Lo, Varsha Tembe, James Freeman, Jenny Lee, Richard A. Scolyer, Kelvin Shenq Woei Siew, Chris Lomma, Adam Cooper, Muhammad A. Khattak, Tarek Meniawy, Georgina V. Long, Matteo S. Carlino, Michael Millward, Mel Ziman - Oncotarget 2015 被引用: 329

  19. Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy

    著者: Gabriela Marsavela, Jenny Lee, Leslie Calapre, Stephen Q. Wong, Michelle R. Pereira, Ashleigh C. McEvoy, Anna Reid, Cleo Robinson, Lydia Warburton, Afaf Abed, Muhammad A. Khattak, Tarek Meniawy, Sarah‐Jane Dawson, Shahneen Sandhu, Matteo S. Carlino, Alexander M. Menzies, Richard A. Scolyer, Georgina V. Long, Benhur Amanuel, Michael Millward, Mel Ziman, Helen Rizos, Elin S. Gray - Clinical Cancer Research 2020 被引用: 63

  20. ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study

    著者: Charlotte Lemech, Ganessan Kichenadasse, Jens‐Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward - Oncogene 2022 被引用: 38

  21. Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.

    著者: Mitesh J. Borad, Alison M. Schram, Richard D. Kim, Suneel D. Kamath, Vaibhav Sahai, Efrat Dotan, Robin Kate Kelley, Mariano Ponz‐Sarvisé, Do‐Youn Oh, Jeffrey Yachnin, Vaia Florou, Philippe A. Cassier, Joon Oh Park, Chih‐Yi Liao, Michael Millward, Florence Ramirez, Fabien Ricard, Antoine Hollebecque, Vivek Subbiah, Lipika Goyal - Journal of Clinical Oncology 2023 被引用: 37

  22. Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy

    著者: Afaf Abed, Ngie Law, Leslie Calapre, Johnny Lo, Vikas Bhat, Samantha Bowyer, Michael Millward, Elin S. Gray - European Journal of Cancer 2022 被引用: 32

  23. Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

    著者: Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey A. Sosman, Leslie A. Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu, René González, Patrick A. Ott, Georgina V. Long, Olivia Gardner, Danièle Ouellet, Yanmei Xu, Douglas J. DeMarini, Ngocdiep T. Le, Kiran Patel, Karl D. Lewis - Journal of Clinical Oncology 2012 被引用: 477

  24. BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer

    著者: Gerald S. Falchook, Michael Millward, David S. Hong, Aung Naing, Sarina A. Piha‐Paul, Steven G. Waguespack, Maria E. Cabanillas, Steven I. Sherman, Bo Ma, Martin Curtis, Vicki Goodman, Razelle Kurzrock - Thyroid 2014 被引用: 229